An observational study in MDS, sponsored by Assiut University. Status unknown. Open to participants aged 40 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-10-05.
Sponsored by Assiut University · Observational
The myelodysplastic syndromes (MDSs) are clonal hematopoietic stem cell disorders characterized by progressive peripheral cytopenia due to ineffective hematopoiesis and a variable risk of transformation into acute myeloid leukemia (AML) .
Clinically, they can range from variable grade of cytopenia to forms not different from AML.
World Health Organization (WHO) MDS classifications from 2002:
included refractory anemia (RA), refractory anemia with ring sideroblasts (RARS), refractory cytopenia with multilineage dysplasia (RCMD), RCMD and ring sideroblasts (RCMDRS), refractory anemia with excess blasts (RAEB), and MDS associated with isolated del(5q) The most recent 2016 WHO MDS classifications are slightly different and include MDS with single lineage or multilineage dysplasia, MDS with ring sideroblasts and single or multilineage dysplasia, MDS with excess blasts, and MDS with isolated del(5q) .
A key first-line treatment option for many patients with symptomatic anemia associated with lower-risk MDS is erythropoiesis-stimulating agents (ESAs) (e.g., epoetin alpha ordarbepoetinalpha),whichmayalsobecombinedwithgranulocyte colony-stimulating factor (G-CSF At least, four mechanisms are recognized to underlie pancytopenia in myelodysplastic syndromes. Based on ferrokinetic studies two distinct mechanisms can be distinguished: (1) hypoproliferative suppressed erythropoiesis and (2) hypoproliferative/ineffective erythropoiesis,The predictive variables for ESAs response in MDS should be divided into biological and clinical variables. Biological variables include: endogenous erythropoietin levels \< 500 U/L and marrow blasts \< 10%, IPSS low INT-1, diagnosis of refractory anemia, and normal karyotype. On clinical plane, transfusion independence and short duration of disease are positive prognostic factors of response to ESAS .
sEPO levels have not only been correlated with response to ESAs. Various studies have also examined whether sEPO levels affect duration of response and overall survival among patients treated with ESAs. Other studies have examined whether sEPO levels can affect response to non-ESA treatments According to International Working Group criteria, erythroid response is considered an increase in hemoglobin level to at least 115 g/L without transfusion need. An increase in hemoglobin level of 15 g/L for patients with non-transfused anemia, or an abolished transfusion need, defines the criteria for partial response. To date, there is only a study assessing that Binocrit (Biosimilar epoetin alfa) is promising for the treatment of anemia of MDS patients. ER positively correlates with improvements in patients' cognitive status and positive changes in QOL after a median time of 2 years, 50% of patients may lose responsivenes to ESAs. Many factors, including depletion of iron, progression to acute myeloid leukemia, may be the underlying cause of loss responsiveness to ESAs. The first study evaluating the duration of response to erythropoietin in MDS patients Serum ferritin (SF) level represents a well-known indicator of the body's iron stores and inflammation. SF is commonly used as a marker of iron overload (defined as SF1000 ng/ mL) but this role has been often questioned, as SF value can be affected by acute infections, inflammations, and even malignant conditions, so that it is also considered as an acute phase protein. Several studies have evaluated tests other than the evaluation of SF level to estimate iron overload, such as Magnetic Resonance Imaging (MRI) and Superconducting Quantum Interference Device (SQUID) biomagnetic liver susceptometry Elevated SF levels represent a common condition among patients with myelodysplastic syndromes (MDS) and appears to be largely related to red blood cell (RBC) transfusion-dependence. However, iron overload is also present among many patients after MDS diagnosis and before RBC transfusion Fibrinogen is a protein produced following inflammation,and hyperfibrinogenemia is known as a poor prognostic factor in various tumors. In recent years, it has also been reported that hyperfibrinogenemia is a poor prognostic factor in diffuse large B-cell lymphoma.
However, whether hyperfibrinogenemia is a prognostic factor in patients with lower-risk myelodysplastic syndromes (MDS) remains unclear
Assiut University is the lead sponsor of 4,901 studies on the registry; 2,098 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.
Counted across the registry records on this site, refreshed daily.
the participants are :adult low risk(IPSS score (2-3) myelodysplastic patients with median age (40-60)
Exclusion Criteria:
Erythropoietin will be given subcutenous to all patients
effect of erythropoietin on MDS prognosis
Time frame: 1 year
No study locations are listed for this record.
This study is status unknown, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assiut University